Keytruda QLEX will offset some of the sales losses associated with Keytruda's patent expiry 

While GlobalData analysts forecast sales of Keytruda QLEX to reach $3.34bn in 2030, this constitutes only a fraction of the revenue lost through the patent expiry of Keytruda.